Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks
B. J. O'Connor, S. Kilfeather, D. Cheung, P. Sips, M. D. Blagden, H. Kafé, C. Biberger (London, Sunderland, Chesterfield, United Kingdom; Schiedam, Utrecht, The Netherlands; Saint Quentin, France; Konstanz, Germany)
Source: Annual Congress 2002 - Severe asthma and COPD
Session: Severe asthma and COPD
Session type: Oral Presentation
Number: 2579
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. J. O'Connor, S. Kilfeather, D. Cheung, P. Sips, M. D. Blagden, H. Kafé, C. Biberger (London, Sunderland, Chesterfield, United Kingdom; Schiedam, Utrecht, The Netherlands; Saint Quentin, France; Konstanz, Germany). Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks. Eur Respir J 2002; 20: Suppl. 38, 2579
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Maintenance of bronchodilation following tiotropium in patients with mild, moderate and severe COPD in one year clinical trials Source: Eur Respir J 2001; 18: Suppl. 33, 331s Year: 2001
Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Long-term efficacy of 1 year anti-inflammatory treatment in paediatric patients with mild persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 379s Year: 2004
Montelukast vs. fluticasone in patients aged 6 to 14 with mild persistent asthma: the MOSAIC study Source: Eur Respir J 2004; 24: Suppl. 48, 377s Year: 2004
Rescue-free days in patients with mild persistent asthma receiving montelukast sodium or an inhaled corticosteroid Source: Eur Respir J 2002; 20: Suppl. 38, 113s Year: 2002
Three month treatment with formoterol in mild asthma: efficacy and side effects Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001
The oral corticosteroid sparing effect of omalizumab in patients with severe chronic asthma: Is there a difference when you become 12 years old? Source: Annual Congress 2011 - Treating childhood asthma Year: 2011
Follow-up results 10 years after early intervention with budesonide or terbutaline in mild persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 667s Year: 2006
Efficacy and safety of single doses of inhaled LAS100977 in patients with mild to moderate asthma Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011
Asthma total costs reduction and clinical improvement after inhaled steroid shift to fluticasone propionate during 1 year in patients with moderate to severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 56s Year: 2002
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
The effect of single dose inhaled budesonide on Amppc20 in patients with mild asthma: a 3 month follow up Source: Eur Respir J 2005; 26: Suppl. 49, 369s Year: 2005
Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 615s Year: 2007
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017
Withdrawal of high-dose inhaled corticosteroids in COPD patients with mild or moderate airflow limitation: a feasibility study in primary care. Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019
Induced sputum in children with mild-moderate persistent asthma: the effect of inhaled corticosteroid treatment Source: Annual Congress 2008 - Assessment of inflammation, hyperresponsiveness and response to exercise in asthmatic children Year: 2008
Efficacy of ruzam in the treatment of patients with mild-to-moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004
Withdrawal of inhaled corticosteroids in COPD patients with mild or moderate airflow limitation: who is suitable for a trial of withdrawal? Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019
Comparative study of 8-weeks treatment of asthma exacerbations in adults with high doses of budesonide versus fluticasone Source: Eur Respir J 2001; 18: Suppl. 33, 97s Year: 2001